You searched for "obstructive"

566 results found

In conversation with Roger Kirby

We were delighted to catch up with Roger Kirby, new President of the RSM, about his illustrious career in urology. Can you tell us a little bit about what led you into the field of urology and what have been...

Mo Belal: a journey of perseverance, resilience and representation

In this interview, we have the privilege of speaking with Mr Mo Belal, a leading consultant urologist whose career and life took an extraordinary turn following a spinal injury. Renowned for his expertise and dedication to patient care, Mr Belal...

Uncovering the fate of small residual fragments

The concept of ‘stone free’ remains an enigma. To some urologists this refers to complete removal of all visible fragments, to others its removal of all ‘clinically significant’ fragments (generally regarded as fragments >2mm), and to some it is absence...

TIP hypospadias repair

This paper by one of the current international leaders in hypospadias surgery looks at the outcome of over 1800 consecutive hypospadias repairs using the tubularised incised plate (TIP) repair, beginning from the first original operation through to sequential modifications over...

The importance of second-look transurethral resection for superficial bladder cancer

This was a prospective study of 100 consecutive patients with a newly diagnosed superficial bladder tumour who underwent a second look transurethral resection of bladder tumour (TURBT) two to six weeks post initial resection. This essentially included pTa multiple and...

Essential Urology: A Guide to Clinical Practice (2nd Edition)

Essential Urology: A Guide to Clinical Practice is an easy read from cover to cover; on average it will take three to four days to finish reading. However, it is packed with information presented in a very succinct manner. The...

FRCS Urol Part 2 Viva Preparation: 80+ High-Yield Scenarios and Realistic Exam Practice

SmashUrology has launched a dedicated FRCS Urol Part 2 viva preparation platform to help candidates bridge the gap between urology knowledge and consultant-level performance in the exam setting. The Viva Bank contains over 80 high-yield scenarios covering commonly tested topics...

Urinary biomarkers for surveillance of non-muscle invasive bladder cancer

Bladder cancer (BC) is the ninth most common cancer worldwide with a yearly incidence of approximately 430,000 cases. There is a male predominance and it is the seventh most common cancer in men worldwide [1]. Non-muscle invasive bladder cancer (NMIBC)...

Recent developments in bladder cancer – NMIBC

Every year, roughly 10,300 individuals are diagnosed with bladder cancer in the UK, making it the 11th most common cancer in the UK, and the eighth most common cancer in men [1]. Of those diagnosed with the disease, 75-85% will...

Activity of enzalutamide in men with mCRPC is affected by prior treatment with abiraterone and / or docetaxel

This study reported on the real-world clinical outcomes of patients at seven academic institutions who were treated with enzalutamide, with the primary objective being to assess the effect of prior therapies (namely abireterone and docetaxel). Three hundred and ten patients...

Utility of biomarkers in the prediction of oncologic outcome after radical cystectomy for SCC

Squamous cell carcinoma (SCC) of the bladder is more commonly seen in Egypt due to schistosomiasis (bilharziasis) and accounts for 2% to 5% of all bladder tumours. Schistosomiasis is found in the bladder vasculature and leads to chronic inflammation causing...

Viveca Biomed acquires Contrelle Activgard – European market launch imminent!

Viveca Biomed is pleased to announce the imminent relaunch of Contrelle Activgard across Europe, starting with the UK market.